Encellin Partners with Breakthrough T1D to Advance Immune-Protected Cell Therapy for Type 1 Diabetes
September 22, 2026
September 22, 2026
NEW YORK, Sept. 22 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, posted the following news release:
* * *
Encellin Partners with Breakthrough T1D to Advance Immune-Protected Cell Therapy for Type 1 Diabetes
*
SAN FRANCISCO, NEW YORK & MONTREAL, Sept. 22, 2026-Encellin, Inc., a clinical-stage biotechnology company developing Encapsulated Cell Replacement Therapy (ENCRT), today announced a par . . .
* * *
Encellin Partners with Breakthrough T1D to Advance Immune-Protected Cell Therapy for Type 1 Diabetes
*
SAN FRANCISCO, NEW YORK & MONTREAL, Sept. 22, 2026-Encellin, Inc., a clinical-stage biotechnology company developing Encapsulated Cell Replacement Therapy (ENCRT), today announced a par . . .